Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00609193 · ClinicalTrials.gov registry record
Functional and Neurochemical Brain Changes in First-episode Bipolar Mania
A clinical trial, sponsored by University of Cincinnati.
- Completed
- Registry status
- 81
- Enrollment target
NCT00609193: Completed study, sponsored by University of Cincinnati.
NCT00609193 is a clinical trial that has completed, run by University of Cincinnati. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00609193 has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
Study Summary
The purpose of this study is to use magnetic resonance imaging (MRI) to examine brain structure, function and chemistry in people with bipolar disorder who are being treated with either quetiapine or lithium. Both of these medicines are FDA-approved to treat mania in adults and lithium is also FDA approved in children; quetiapine is commonly used in children with mania, but is not FDA approved for this indication in this age group.
Interventions
- DRUG quetiapine
- DRUG lithium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2008-01 |
| Est. Completion | 2015-07 |
What the finished NCT00609193 record still lists
NCT00609193 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 81 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which quetiapine is the first listed.
NCT00609193 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00609193 about?
NCT00609193 is a clinical study titled "Functional and Neurochemical Brain Changes in First-episode Bipolar Mania". The purpose of this study is to use magnetic resonance imaging (MRI) to examine brain structure, function and chemistry in people with bipolar disorder who are being treated with either quetiapine or lithium. Both of these medicines are FDA-approved to treat mania in adults and lithium is also FDA a...
What is the current status of trial NCT00609193?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2008-01. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00609193?
The interventions under investigation include: quetiapine (DRUG), lithium (DRUG).
Who is sponsoring clinical trial NCT00609193?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia